JNCI Journal of the National Cancer Institute最新文献

筛选
英文 中文
RE: Predicting persistent opioid use, abuse, and toxicity among cancer survivors. 预测癌症幸存者中阿片类药物的持续使用、滥用和毒性。
IF 9.9 1区 医学
JNCI Journal of the National Cancer Institute Pub Date : 2025-05-01 DOI: 10.1093/jnci/djaf019
Obinna O Oleribe
{"title":"RE: Predicting persistent opioid use, abuse, and toxicity among cancer survivors.","authors":"Obinna O Oleribe","doi":"10.1093/jnci/djaf019","DOIUrl":"10.1093/jnci/djaf019","url":null,"abstract":"","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":"1076-1077"},"PeriodicalIF":9.9,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143074350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Limiting surveillance in individuals with the Palestinian TP53 p. R181C founder variant-is it too soon to draw conclusions? 限制对巴勒斯坦TP53 p. R181C创生变异个体的监测——下结论为时过早吗?
IF 9.9 1区 医学
JNCI Journal of the National Cancer Institute Pub Date : 2025-05-01 DOI: 10.1093/jnci/djaf009
Meis Omran, David Malkin
{"title":"Limiting surveillance in individuals with the Palestinian TP53 p. R181C founder variant-is it too soon to draw conclusions?","authors":"Meis Omran, David Malkin","doi":"10.1093/jnci/djaf009","DOIUrl":"10.1093/jnci/djaf009","url":null,"abstract":"","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":"819-821"},"PeriodicalIF":9.9,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143364934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prognostic factors in localized pancreatic ductal adenocarcinoma after neoadjuvant therapy and resection: a systematic review and meta-analysis. 新辅助治疗和切除术后局部胰腺导管腺癌的预后因素:系统综述和 Meta 分析。
IF 9.9 1区 医学
JNCI Journal of the National Cancer Institute Pub Date : 2025-05-01 DOI: 10.1093/jnci/djae294
Ammar A Javed, Alyssar Habib, Omar Mahmud, Asad Saulat Fatimi, Mahip Grewal, Nabiha Mughal, Jin He, Christopher L Wolfgang, Lois Daamen, Marc G Besselink
{"title":"Prognostic factors in localized pancreatic ductal adenocarcinoma after neoadjuvant therapy and resection: a systematic review and meta-analysis.","authors":"Ammar A Javed, Alyssar Habib, Omar Mahmud, Asad Saulat Fatimi, Mahip Grewal, Nabiha Mughal, Jin He, Christopher L Wolfgang, Lois Daamen, Marc G Besselink","doi":"10.1093/jnci/djae294","DOIUrl":"10.1093/jnci/djae294","url":null,"abstract":"<p><strong>Background: </strong>Prognostic markers for overall survival in resected pancreatic ductal adenocarcinoma are well established but remain unclear following neoadjuvant therapy. This systematic review and meta-analysis aimed to determine factors associated with overall survival following neoadjuvant therapy in resected pancreatic ductal adenocarcinoma.</p><p><strong>Methods: </strong>The PubMed, Embase, Scopus, Web of Science, and Cochrane CENTRAL databases were systematically searched from January 2010 until May 2024. Studies that reported univariable and multivariable hazard ratios were included if patients underwent neoadjuvant therapy and resection for localized pancreatic ductal adenocarcinoma. Study quality assessment was performed using the Newcastle-Ottawa scale. Meta-analysis was performed using generic inverse-variance random-effects models.</p><p><strong>Results: </strong>Among 2208 unique articles identified by the search, 92 were included in the meta-analysis. Of these, 85 were of \"good\" and 7 of \"poor\" quality. The neoadjuvant therapy regimen was described in 84 studies of which 62 included patients treated with FOLFIRINOX. Margin status, nodal disease, American Joint Committee on Cancer (AJCC) T-stage, and normalization of cancer antigen 19-9 (CA19-9) after neoadjuvant therapy were prognostic for overall survival, whereas age, sex, perineural invasion, baseline tumor size, and baseline CA19-9 were not. The test for subgroup differences between ypN substages was not statistically significant in the multivariable model. Neoadjuvant FOLFIRINOX was associated with better survival than other regimens.</p><p><strong>Conclusions: </strong>This meta-analysis identified margin status, nodal disease, AJCC T-stage, and normalization of CA19-9 after neoadjuvant therapy as prognostic factors for overall survival in patients with resected localized pancreatic ductal adenocarcinoma following neoadjuvant therapy.</p>","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":"840-867"},"PeriodicalIF":9.9,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142675871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
RE: Long-term survival across Breslow thickness categories: findings from a population-based study of 210 042 Australian melanoma patients. RE:支气管厚度类别的长期生存率:来自21042名澳大利亚黑色素瘤患者的基于人群的研究结果。
IF 9.9 1区 医学
JNCI Journal of the National Cancer Institute Pub Date : 2025-05-01 DOI: 10.1093/jnci/djaf025
Fangzheng Han, Huaimin Liu
{"title":"RE: Long-term survival across Breslow thickness categories: findings from a population-based study of 210 042 Australian melanoma patients.","authors":"Fangzheng Han, Huaimin Liu","doi":"10.1093/jnci/djaf025","DOIUrl":"10.1093/jnci/djaf025","url":null,"abstract":"","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":"1080-1081"},"PeriodicalIF":9.9,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143255513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Enhancing capacity for primary care research in cancer survivorship: National Cancer Institute meeting report. 增强癌症幸存者初级保健研究能力:国家癌症研究所会议报告。
IF 9.9 1区 医学
JNCI Journal of the National Cancer Institute Pub Date : 2025-05-01 DOI: 10.1093/jnci/djae276
Shawna V Hudson, Michelle A Mollica, Crystal Reed, Erin E Hahn, Denalee M O'Malley, Archana Radhakrishnan, Jennifer Klemp, Emily Tonorezos
{"title":"Enhancing capacity for primary care research in cancer survivorship: National Cancer Institute meeting report.","authors":"Shawna V Hudson, Michelle A Mollica, Crystal Reed, Erin E Hahn, Denalee M O'Malley, Archana Radhakrishnan, Jennifer Klemp, Emily Tonorezos","doi":"10.1093/jnci/djae276","DOIUrl":"10.1093/jnci/djae276","url":null,"abstract":"<p><p>Many components of long-term cancer follow-up and survivorship care are managed in the primary care context. Given the important role that primary care has in survivorship care, it is critical to ensure that teams in these settings are prepared to address long-term needs. Evidence-based strategies to deliver survivorship care in primary care settings in the United States remain limited. The National Cancer Institute Office of Cancer Survivorship conducted a day-long virtual event, Enhancing Capacity for Primary Care Research in Cancer Survivorship: A Workshop for Action, on February 28, 2024, to discuss research needs addressing the intersection between primary care and cancer survivorship. Topics discussed to advance this area of research included system-level interventions, methods and measurement, and mentorship and research team building, especially for early career researchers. The purpose of this report is to provide a summary of the key findings. Gaps and opportunities include (1) health systems-level research that investigates primary care practice-level capacity, (2) identification and characterization of the targeted cancer survivor populations for primary care research, (3) leveraging electronic medical records to track relevant patient outcomes throughout survivorship, and (4) development and creation of communities of practice to support and build research capacity. Team science approaches were identified as a core strategy to advance survivorship research. The meeting closed with a reflection and call to action focused on building collaborations that span different research areas, disciplines, and organizations and building a broad network of a primary care practice-focused research.</p>","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":"827-832"},"PeriodicalIF":9.9,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12058249/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142582894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Diverse Aspects of Uterine Serous Cancer: an NCI workshop on the status of and opportunities for advancement of research. 子宫浆液性癌的多样性:美国国家癌症研究所(NCI)关于研究现状和发展机遇的研讨会。
IF 9.9 1区 医学
JNCI Journal of the National Cancer Institute Pub Date : 2025-05-01 DOI: 10.1093/jnci/djae277
Naveena B Janakiram, Megan A Clarke, Mihoko Kai, Tiffany A Wallace, Sandra Russo, Toby T Hecht, Elise C Kohn, Brandy Heckman-Stoddard
{"title":"The Diverse Aspects of Uterine Serous Cancer: an NCI workshop on the status of and opportunities for advancement of research.","authors":"Naveena B Janakiram, Megan A Clarke, Mihoko Kai, Tiffany A Wallace, Sandra Russo, Toby T Hecht, Elise C Kohn, Brandy Heckman-Stoddard","doi":"10.1093/jnci/djae277","DOIUrl":"10.1093/jnci/djae277","url":null,"abstract":"<p><p>The marked increase in the incidence and mortality associated with endometrial cancer over the past 2 decades is driven in part by rising rates of higher-grade, more aggressive endometrial cancers with variations in TP53, uterine serous cancers and their dedifferentiated component, uterine carcinosarcomas. Uterine serous cancer rates have been increasing among all racial and ethnic groups, with higher rates of this aggressive uterine cancer in Black women. The National Cancer Institute hosted a workshop in June 2023 to examine the diverse aspects of uterine serous cancers across epidemiology, biology, and molecular genetics and to advance knowledge from basic to preclinical and translational efforts. Key stakeholders, including basic scientists, clinical investigators, and patient advocates, came together to identify critical research gaps that, when addressed, would facilitate more comprehensive and rapid progress in understanding and ultimately treating uterine serous cancers across all patients. The National Cancer Institute released a supplemental funding opportunity (NOT-CA-24-044) in spring 2024 to facilitate rapid translation of these recommendations.</p>","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":"833-839"},"PeriodicalIF":9.9,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12058257/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142582938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Response to Han and Liu. 回应韩、刘。
IF 9.9 1区 医学
JNCI Journal of the National Cancer Institute Pub Date : 2025-05-01 DOI: 10.1093/jnci/djaf026
Serigne N Lo, Alexander H R Varey, Sydney Ch'ng, Richard A Scolyer, John F Thompson
{"title":"Response to Han and Liu.","authors":"Serigne N Lo, Alexander H R Varey, Sydney Ch'ng, Richard A Scolyer, John F Thompson","doi":"10.1093/jnci/djaf026","DOIUrl":"10.1093/jnci/djaf026","url":null,"abstract":"","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":"1082-1083"},"PeriodicalIF":9.9,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143364938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recognizing IPMN-derived pancreatic cancer as a specific entity requiring prospective clinical studies: a call for international collaboration. 认识到ipmn衍生的胰腺癌是一种需要前瞻性临床研究的特殊实体:呼吁国际合作。
IF 9.9 1区 医学
JNCI Journal of the National Cancer Institute Pub Date : 2025-05-01 DOI: 10.1093/jnci/djaf037
Joseph R Habib, Ammar A Javed, I Quintus Molenaar, Christopher L Wolfgang, Marc G Besselink
{"title":"Recognizing IPMN-derived pancreatic cancer as a specific entity requiring prospective clinical studies: a call for international collaboration.","authors":"Joseph R Habib, Ammar A Javed, I Quintus Molenaar, Christopher L Wolfgang, Marc G Besselink","doi":"10.1093/jnci/djaf037","DOIUrl":"10.1093/jnci/djaf037","url":null,"abstract":"","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":"1084-1085"},"PeriodicalIF":9.9,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143407250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
On the road to new drugs in clinical oncology: benefit of phase 2 trials. 在通往临床肿瘤学新药的道路上:ii期试验的益处。
IF 9.9 1区 医学
JNCI Journal of the National Cancer Institute Pub Date : 2025-05-01 DOI: 10.1093/jnci/djaf023
Howard S Hochster
{"title":"On the road to new drugs in clinical oncology: benefit of phase 2 trials.","authors":"Howard S Hochster","doi":"10.1093/jnci/djaf023","DOIUrl":"10.1093/jnci/djaf023","url":null,"abstract":"","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":"825-826"},"PeriodicalIF":9.9,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143492183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Adolescents and young adults with germline CDH1 variants and the risk of overtreatment. 患有种系CDH1变异的青少年和年轻人与过度治疗的风险。
IF 9.9 1区 医学
JNCI Journal of the National Cancer Institute Pub Date : 2025-05-01 DOI: 10.1093/jnci/djaf002
Amber F Gallanis, Cassidy Bowden, Rachael Lopez, Grace-Ann Fasaye, David Lang, Jill Rothschild, M Constanza Camargo, Jonathan M Hernandez, Anjali Rai, Theo Heller, Andrew M Blakely, Jeremy L Davis
{"title":"Adolescents and young adults with germline CDH1 variants and the risk of overtreatment.","authors":"Amber F Gallanis, Cassidy Bowden, Rachael Lopez, Grace-Ann Fasaye, David Lang, Jill Rothschild, M Constanza Camargo, Jonathan M Hernandez, Anjali Rai, Theo Heller, Andrew M Blakely, Jeremy L Davis","doi":"10.1093/jnci/djaf002","DOIUrl":"10.1093/jnci/djaf002","url":null,"abstract":"<p><strong>Background: </strong>Adolescents and young adults (AYA) with germline CDH1 variants are at risk of overtreatment when precancer lesions are detected with endoscopic screening. We characterize diffuse-type gastric cancer prevalence and survival in AYA managed with prophylactic total gastrectomy (PTG) or endoscopic surveillance.</p><p><strong>Methods: </strong>Prospective cohort study of 188 individuals aged 39 and younger enrolled from January 27, 2017, to May 1, 2023. Clinicopathological data, prevalence of early gastric signet ring cell (SRC) lesions, advanced gastric cancer diagnoses, and cancer-specific survival were measured.</p><p><strong>Results: </strong>Among 188 AYA patients, 104 chose surveillance and 67 pursued PTG for management of elevated gastric cancer risk. AYA who enrolled early in the study period and had SRC lesions detected on preoperative endoscopy were more likely to elect for PTG compared with surveillance. SRC lesions were detected on preoperative endoscopy in 48% of patients who subsequently had PTG, and yet nearly all (93%, 62/67) had multifocal SRC (pT1aN0) on final pathology. Median age at enrollment (30 vs 31 years, P = .21), biological sex (P = .17), and median number of family members with gastric cancer (3 vs 4, P = .14) were not different between groups. No patients under surveillance developed advanced cancer or developed cancer recurrence after PTG with a median follow-up of 2.5 years (IQR = 1.6-4.0) from initial endoscopy.</p><p><strong>Conclusions: </strong>Cancer-specific outcomes were not different in AYA who harbored SRC and were managed with surveillance or PTG. Lack of cancer-specific deaths and low prevalence of advanced gastric cancer underscore the risk of overtreatment of SRC lesions and suggest that active surveillance is warranted.</p>","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":"1027-1035"},"PeriodicalIF":9.9,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12058253/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142931725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信